#1 Ranked Children’s Hospital by U.S. News & World Report
MyPatients provides referring primary care providers with secure access to their patients’ information.
Boston Children's has launched the world's 1st program dedicated to offering hand transplants to children who qualify.
Innovation insider is a semi-monthly e-newsletter analyzes innovations at Boston Children’s, other academic medical centers and from industry.
Read the latest blog by a Boston Children's doctor, clinician or staff member.
There are many ways you can help children and their families get the care they need.
The Neurofibromatosis Program at Boston Children’s Hospital is one the few sites that’s part of a national neurofibromatosis (NF) clinical trials consortium. This means that any new clinical trials opening in the area of NF1 or NF2 will involve our program here at Boston Children’s.
We’re moving into a whole new era of medicine that features targeted treatments for individuals with NF2. For the first time these treatments, as part of clinical trials, will be available in children.
There is also a national NF clinical trial consortium, funded by the U.S. Department of Defense, that includes some of the largest NF centers throughout the country, both for NF1 and NF2. The goal of this consortium is to create targeted treatments for the various types of tumors accompanying NF and related disorders.
If you’d like to find out more about our research and clinical trials or see whether your child might be a candidate, please talk to your child’s doctor or email us at firstname.lastname@example.org.
We are grateful to have been ranked #1 on U.S. News & World Report's list of the best children's hospitals in the nation for the third year in a row, an honor we could not have achieved without the patients and families who inspire us to do our very best for them. Thanks to you, Boston Children's is a place where we can write the greatest children's stories ever told.”